Abstract
Whether to treat hyperuricemia uncomplicated by articular gout, urolithiasis, or uric acid nephropathy is an exercise in clinical judgment and universal agreement is lacking. Patients with coronary artery disease, chronic kidney disease, and early onset hypertension with persistent hyperuricemia are likely to be benefited with urate-lowering therapy. The paradigm of the causative association of hyperuricemia with cardiovascular and chronic kidney diseases seems to have progressed from skepticism to increasing evidence of a true relationship. Although such evidences are mounting, they are not enough to support pharmacotherapy for all patients with asymptomatic hyperuricemia. Further studies are needed to determine which patients are likely to get beneficial effects from pharmacotherapy and the minimum threshold of uric acid level required to experience clinical benefits.
Similar content being viewed by others
References
Oda M, Satta Y, Takenaka O et al (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640–653
Kratzer JT, Lanaspa MA, Murphy MN et al (2014) Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A 111:3763–3768
Johnson RJ, Titte S, Cade JR et al (2005) Uric acid, evolution and primitive cultures. Semin Nephrol 2005(25):3–8
Watanabe S, Kang DH, Feng L et al (2002) Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40:355–360
Orowan E (1955) The origin of man. Nature 175:683–684
Alonso A, Rodriguez LA, Logroscino G et al (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69:1696–1700
Shen C, Guo Y, Luo W et al (2013) Serum urate and the risk of Parkinson’s disease: results from a meta-analysis. Can J Neurol Sci 40:73–79
Euser SM, Hofman A, Westendorp RG et al (2009) Serum uric acid and cognitive function and dementia. Brain 132(Pt 2):377–382 2009
Lu N, Dubreuil M, Zhang Y et al (2016) Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 75:547–551
Guerrero AL, Gutierrez F, Iglesias F et al (2011) Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 32:347–350
Moccia M, Lanzillo R, Costabile T et al (2015) Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. J Neurol 262:961–967
Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington’s disease progression. Mol Disord 25:224–228
Hershfield MS, Roberts LJ 2nd, Ganson NJ et al (2010) Treating gout with pegloticase, a PEGylatedurate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA 107:14351–14356
Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:269–275
Kang DH, Han L, Ouyang X et al (2005) Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 25:425–433
Kang DH, Nakagawa T, Feng L et al (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897
Prasad Sah OS, Qing YX (2015) Associations between hyperuricemia and chronic kidney disease: a review. Nephrourol Mon 7(3):e27233
Pillinger MH, Goldfarb DS, Keenan RT (2010) Gout and its comorbidities. Bull NYU Hosp Jt Dis. 68:199–203
Goicoechea M, de Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388–1393
Dehghan A, van Hoek M, Sijbrands EJ et al (2008) High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31:361–362
Krishnan E, Pandya BJ, Chung L et al (2012) Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol 176(2):108–116
Yoo TW, Sung KC, Shin HS et al (2005) Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69(8):928–933
Campion EW, Glynn RJ, Delabry LO (1987) Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 82:421–426
Langford HG, Blaufox MD, Borhani NO et al (1987) Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 147:645–649
Lin KC, Lin HY, Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27:1501
Choi HK, Atkinson K, Karlson EW et al (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277
Choi HK, Atkinson K, Karlson EW et al (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093
Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men (2005) the health professionals follow-up study. Arch Intern Med 165:742
Yu T, Gutman AB (1967) Uric acid nephrolithiasis in gout: predisposing factors. Ann Intern Med 67:1133–1148
Fessel JW (1979) Renal outcomes of gout and hyperuricemia. Am J Med 67:74–82
Dincer HE, Dincer AP, Levinson DJ (2002) Asymptomatic hyperuricemia: treat or not to treat. Cleveland clinic J Med 69(8):594–608
Lu CC, Wu SK, Chung WS, Lin LH, Hung TW, Yeh CJ et al (2017) Metabolic characteristics and renal dysfunction in 65 patients with tophi prior to gout. Clinical Rheumatol 36(8):1903–1909
Wang J, Qin T, Chen J, Li Y, Wang L, Huang H et al (2014) Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoSONE 9(12):e114259. https://doi.org/10.1371/ journal. pone.0114259
Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63(1):102–110
Perlstein TS, Gumieniak O, Williams GH et al (2006) Uric acid and the development of hypertension: the normative aging study. Hypertension 48:1031–1036
Mellen PB, Bleyer AJ, Erlinger TP et al (2006) Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 48:1037–1042
Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49:298–303
Forman JP, Choi H, Curhan GC (2009) Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med 169:155–162
Leite MA (2011) Uric acid and fibrinogen: age-modulated relationships with blood pressure components. J Human Hypertens 25:476–483
Grayson PC, Kim SY, Lavalley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 63:102–110
Silverstein D, Srivaths PR, Mattison P et al (2011) Serum uric acid is associated with high blood pressure in pediatric hemodialysis patients. Pediatr Nephrol 26:1123–1128
Loeffler LF, Navas-Acien A, Brady TM et al (2012) Uric acid level and elevated blood pressure in US adolescents. Hypertension 59:811–817
Gaffo AL (2013) Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis 72(8):1321–1327. https://doi.org/10.1136/annrheumdis-2012-201916
Kuwabara M, Niwa K, Nishi Y et al (2014) Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res 37:785–789. PubMed
Cui LF, Shi HJ, Wu SL et al (2017) Association of serum uric acid and risk of hypertension in adults: a prospective study of Kailuan Corporation cohort. Clin Rheum 36(5):1103–1110
Kuwubara M, Niwa K, Hisatone I et al (2017) Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases—Five-Year Japanese Cohort Study. Hypertension 69:1036–1044
Sundstrom J, Sullivan L, D’Agostino RB et al (2005) Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45:28–33
Feig DI, Johnson RJ (2003) Hyperuricemia in childhood primary hypertension. Hypertension 42:247–252
Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932
Soletsky B, Feig DI (2012) Uric acid reduction rectifies pre hypertension in obese adolescents. Hypertension 60:1148–1156
Beattie CJ, Fulton RL, Higgins P (2014) Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension 64:1102–1107
Nakanishi N, Okamato M, Yoshida H et al (2003) Serum uric acid and the risk of developing hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 18:523–530
Baldwin W, McRae S, Marek G et al (2011) Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60:1258–1269
Feig DI, Nakagawa T, Karumanchi SA et al (2004) Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 66:281–287
Murray T, Goldberg M (1975) Chronic interstitial nephritis: etiologic factors. Ann Intern Med 82:453–459
Li L, Yang C, Zhao Y et al (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122. https://doi.org/10.1186/1471-2369-15-122
Johnson RJ, Nakgawa T et al (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28(9):2221–2228
Tsai C-W, Lin S-Y, Kuo C-C et al (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini review. PLoSONE 12(1):e0170397. https://doi.org/10.1371/journal.pone0170393
Fessel WJ (1979) Renal outcomes of gout and hyperuricemia. Am J Med 67:74–82
Obermayr R, Temmi C, Gutjahr G et al (2008) Elevated uric acid increases the risk for kidney disease. J Am SocNephrol 19(12):2407–2413
Weiner D, Tighiouart H, Elsayed E, Griffith J, Salem D, Levey AS (2008) Uric acid and incident kidney disease in the community. J Am SocNephrol 19:1204–1211
Whelton A, Macdonald PA, Chefo S, Gunawardhana L (2013) Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med 125(1):106–114
Sircar D, Chatterjee S, Wikhom R et al (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66(6):945–950
Abbott RD, Brand FN, Kannel WB et al (1988) Gout and coronary artery disease: the Framingham study. J Clin Epidemiol 41(3):237–242
Reedman DS, Williamson DF, Gunter EW, Byers T (1995) Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141:637–644
Culleton BF, Larson MB, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann.Int Med 131:7–13
Feig DI, Kang D-H, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811–1821
Kim SY, Guevara JP, Mi Kim K et al (2010) Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 62(2):170–180. https://doi.org/10.1002/acr.20065
Zuo T, Liu X, Jiang L (2016) Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord 16:207. https://doi.org/10.1186/s12872-016-0379-z
Kuo CF, Yu KH, See LC et al (2013) Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 52(1):111–117
Palmer TM, Nordestgaard BG, Benn M (2013) Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 347:f4262. https://doi.org/10.1136/bmj.f4262
Capuano V, Marchese F, Capuano R et al (2017) Hyperuricemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy. J Cardiovasc Med 18(3):159–164
Anker SD, Doehner W, Rauchhaus M et al (2003) Uric acid and survival in chronic heart failure. Circulation 107:1991–1199
Kim H, Seok-hyung K, Choi AR (2017) Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: a single-center cross-sectional study. Medicine 96(14):e6565. https://doi.org/10.1097/MD.0000000000006565
Becker MA, Jolly M (2006) Hyperuricemia and associated diseases. Rheum Dis Clin N Am 32:275–293
Burns CM, Wortmann RL (2017) Clinical features and treatment of gout. In: Firestein GS, Budd RC, Gabriel SC, McInnes IB, O'Dell JR (eds) Kelley and Firestein’s textbook of rheumatology, 10th edn. Elsevier, Philadelphia, p 1620–1644
Richette P, Doherty M, Pascual E et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 78:29–42. https://doi.org/10.1136/annrheumdis--209707
Zhang Y, Neogi T, Chen C (2012) Cherry consumption and the risk of recurrent gout attacks. Arthritis Rheum 64(12):4004–4011. https://doi.org/10.1002/art.34677
Park KY, Kim HJ, Ahn HS (2016) Effects of coffee consumption on serum uric acid: systematic review and meta-analysis. Semin Arthritis Rheum 45(5):580–586
Juraschek SP, Miller ER, Gelber AC (2011) Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 63(9):1295–1306 2011
Qin X, Li Y, He M et al (2017) Folic acid therapy reduces serum uric acid in hypertensive patients: a sub study of the China Stroke Primary Prevention Trial (CSPPT). Am J Clin Nutr 105(4):882–889
Hosoya T, Sasaki T, Ohashi T (2017) Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clinical Rheumatology 36(3):649–656
Stamp L, Dalbeth N (2017) Urate lowering therapy for asymptomatic hyperuricemia. A need for caution Sem Arthritis Rheum 46:457–464
Levy G, Cheetham TC (2015) Is it time to start treating asymptomatic hyperuricemia? Am J Kidney Dis 66(6):933–935
Ramirez MEG, Bargman JM (2017) Treatment of asymptomatic hyperuricemia in chronic kidney disease: a new target in an old enemy—a review. J Adv Res 8(5):551–554
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Paul, B.J., Anoopkumar, K. & Krishnan, V. Asymptomatic hyperuricemia: is it time to intervene?. Clin Rheumatol 36, 2637–2644 (2017). https://doi.org/10.1007/s10067-017-3851-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-017-3851-y